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Summary
Background We aimed to investigate whether gatiﬂ oxacin, a new generation and aﬀ ordable ﬂ uoroquinolone, is better 
than chloramphenicol for the treatment of uncomplicated enteric fever in children and adults.
Methods We did an open-label randomised superiority trial at Patan Hospital, Kathmandu, Nepal, to investigate 
whether gatiﬂ oxacin is more eﬀ ective than chloramphenicol for treating uncomplicated enteric fever. Children 
and adults clinically diagnosed with enteric fever received either gatiﬂ oxacin (10 mg/kg) once a day for 7 days, or 
chloramphenicol (75 mg/kg per day) in four divided doses for 14 days. Patients were randomly allocated 
treatment (1:1) in blocks of 50, without stratiﬁ cation. Allocations were placed in sealed envelopes opened by the 
study physician once a patient was enrolled into the trial. Masking was not possible because of the diﬀ erent 
formulations and ways of giving the two drugs. The primary outcome measure was treatment failure, which 
consisted of at least one of the following: persistent fever at day 10, need for rescue treatment, microbiological 
failure, relapse until day 31, and enteric-fever-related complications. The primary outcome was assessed in all 
patients randomly allocated treatment and reported separately for culture-positive patients and for all patients. 
Secondary outcome measures were fever clearance time, late relapse, and faecal carriage. The trial is registered on 
controlled-trials.com, number ISRCTN 53258327.
Findings 844 patients with a median age of 16 (IQR 9–22) years were enrolled in the trial and randomly allocated a 
treatment. 352 patients had blood-culture-conﬁ rmed enteric fever: 175 were treated with chloramphenicol and 
177 with gatiﬂ oxacin. 14 patients had treatment failure in the chloramphenicol group, compared with 12 in the 
gatiﬂ oxacin group (hazard ratio [HR] of time to failure 0·86, 95% CI 0·40–1·86, p=0·70). The median time to 
fever clearance was 3·95 days (95% CI 3·68–4·68) in the chloramphenicol group and 3·90 days (3·58–4·27) in the 
gatiﬂ oxacin group (HR 1·06, 0·86–1·32, p=0·59). At 1 month only, three of 148 patients were stool-culture positive 
in the chloramphenicol group and none in the gatiﬂ oxacin group. At the end of 3 months only one person had a 
positive stool culture in the chloramphenicol group. There were no other positive stool cultures even at the end of 
6 months. Late relapses were noted in three of 175 patients in the culture-conﬁ rmed chloramphenicol group and 
two of 177 in the gatiﬂ oxacin group. There were no culture-positive relapses after day 62. 99 patients (24%) 
experienced 168 adverse events in the chloramphenicol group and 59 (14%) experienced 73 events in the 
gatiﬂ oxacin group.
Interpretation Although no more eﬃ  cacious than chloramphenicol, gatiﬂ oxacin should be the preferred treatment 
for enteric fever in developing countries because of its shorter treatment duration and fewer adverse events.
Funding Wellcome Trust.
Introduction
Enteric fever is a disease that predominantly aﬀ ects 
children and is caused by the faecal–oral transmission1 
of Salmonella enterica serotype Typhi (S typhi) and 
Salmonella enterica Paratyphi A (S paratyphi A). There 
are an estimated 26 million infections and over 
200 000 deaths caused by the disease worldwide each 
year.2 In parts of south Asia, the incidence of enteric 
fever in children can be as high as 573 cases per 
100 000 person years.3
Chloramphenicol was the standard treatment for 
enteric fever from the 1950s1,4,5 until the development 
and spread of multidrug resistant (MDR; deﬁ ned as 
resistance to all ﬁ rst-line antibiotics: chloramphenicol, 
amoxicillin, and co-trimoxazole) S typhi and S paratyphi 
A in the early 1990s. Subsequently, ﬂ uoroquinolones 
became ﬁ rst choice for the treatment of enteric fever. 
However, increased resistance to the older generation 
ﬂ uoroquinolones (ciproﬂ oxacin and oﬂ oxacin) has 
emerged. This reduces the options for treatment, and 
raises the spectre of fully resistant enteric fever.1,6
Conﬂ icting reports have emerged from randomised 
controlled trials with relatively small sample sizes that 
assessed older ﬂ uoroquinolones (ciproﬂ oxacin and 
oﬂ oxacin) versus chloramphenicol for the treatment of 
enteric fever.1,7 Additionally, no trials have been done to 
investigate the eﬃ  cacy of chloramphenicol versus a 
newer ﬂ uoroquinolone, such as gatiﬂ oxacin, in the 
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treatment of enteric fever in children.1,8 Recent reports 
suggest a general decline in the prevalence of MDR 
typhoid fever in Asia,9–15 and two recent studies of 
patients with enteric fever in Kathmandu, Nepal 
reported a low prevalence of chloramphenicol resistance 
in S typhi and S paratyphi A isolates: nine (1·7%) in 
522 strains of S typhi16 and three (1·2%) of 247 strains of 
S paratyphi A.10
Gatiﬂ oxacin was eﬀ ective in the treatment of nalidixic-
acid-resistant enteric fever in two previous randomised 
trials done in Nepal16 and Vietnam.17 The drug targets 
both DNA gyrase and topoisomerase IV,18,19 and hence is 
less inhibited by the common mutations of the 
gyrA gene of S typhi than are ciproﬂ oxacin or oﬂ oxacin.
We designed a randomised controlled trial to assess 
whether gatiﬂ oxacin had superior eﬃ  cacy compared 
with chloramphenicol in adults and children with 
un comp licated enteric fever in Nepal.
Methods
Patients
The study physicians enrolled patients who presented 
to the outpatient or emergency department of Patan 
Hospital, Lalitpur, Nepal from May 2, 2006, to August 30, 
2008. Patients with fever for more than 3 days who were 
clinically diagnosed to have enteric fever (undiﬀ eren-
tiated fever with no clear focus of infection on 
preliminary physical exam and laboratory tests) whose 
residence was in a predesignated area of about 20 km² 
in urban Lalitpur and who gave fully informed written 
consent were eligible for the study. Exclusion criteria 
were pregnancy or lactation, age under 2 years or weight 
Figure 1: Trial proﬁ le
*Two culture-positive patients in both the chloramphenicol and glatiﬂ oxacin groups were lost to follow-up before day 8.
1151 patients from the study area assessed for eligibility                 
298 excluded before randomisation
         118 already on antibiotics
           67 refused consent
           57 could not arrange to be followed up
           14 child refused to take part
           25 other reasons for exclusion                 
853 randomised
9 removed after randomisation
    6 dropped out before single dose            
    1 blood could not be drawn                      
    2 mistakenly randomised        
844 analysed
134 followed up at 
         month 6 (76·57%) 
156 followed up at 
         month 3 (89·14%) 
165 followed up at 
         month 1 (94·29%) 
169 followed up at 
         day 15 (96·57%) 
173 followed up at 
         day 8 (98·86%)* 
204 followed up at 
         month 3 (83·95%) 
220 followed up at 
         month 1 (90·53%) 
221 followed up at 
         day 15 (90·95%) 
239 followed up at 
         day 8 (98·35%) 
139 followed up at 
         month 6 (78·53%) 
154 followed up at 
         month 3 (87·01%) 
169 followed up at 
         month 1 (95·48%) 
168 followed up at 
         day 15 (94·92%) 
175 followed up at 
         day 8 (98·87%)* 
206 followed up at 
         month 3 (82·73%) 
217 followed up at 
         month 1 (87·15%) 
216 followed up at 
         day 15 (86·75%) 
235 followed up at 
         day 8 (94·38%) 
175 culture positive 243 culture negative 177 culture positive 249 culture negative 
5 other diagnoses
    1 pneumonia                      
    1  liver abscess               
    2 infectious
hepatitis                    
    1 mumps
7 other diagnoses
    1 pneumonia                      
    2 malaria                            
    1 liver abscess                
    2 infectious
 hepatitis                    
    1 Acinetobacter sp
418 chloramphenicol group  426 gatiﬂoxacin group
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less than 10 kg, shock, jaundice, gastrointestinal 
bleeding, or any other signs of severe typhoid fever, 
previous history of hypersensitivity to either of the trial 
drugs, or known previous treatment with chlor-
amphenicol, quinolone antibiotic, third generation 
cephalosporin, or macrolide within 1 week of hospital 
admission. Patients who had received amoxicillin or co-
trimoxazole were included as long as they did not show 
evidence of clinical response. Ethical approval was 
granted by both Nepal Health Research Council and 
Oxford Tropical Research Ethics Committee.
Randomisation and masking
Randomisation was done in blocks of 50 without 
stratiﬁ cation by an administrator otherwise not involved 
in the trial. The random allocations were placed in 
sealed opaque envelopes, which were kept in a locked 
drawer and opened by the study physician once each 
patient was enrolled into the trial after meeting the 
inclusion and exclusion criteria. Patients were enrolled 
in the order they presented and the sealed envelopes 
were opened in strict numerical sequence. Masking was 
not possible because of the diﬀ erent formulations and 
ways of giving the two drugs.
Procedures
Each enrolled patient was randomly assigned to 
treatment with either gatiﬂ oxacin tablets (400 mg) 10 mg 
per kg per day in a single oral dose for 7 days or 
chloramphenicol capsules (250 mg or 500 mg) 75 mg per 
kg per day in four divided oral doses for 14 days. 
Gatiﬂ oxacin tablets were cut and weighed and the 
patients’ daily doses were prepared in sealed plastic bags. 
The per-protocol planned duration of chloramphenicol 
treatment of 14 days was modiﬁ ed for blood-culture-
negative patients, who received at least 8 days of 
chloramphenicol and stopped either on day 8 or 5 days 
after being afebrile, whichever came later. Gatiﬂ oxacin 
was given for 7 days in all patients.
After enrolment, patients were managed as outpatients 
and seen by trained community medical auxiliaries 
(CMAs), as described previously.16 The CMAs made a 
visit to each patient’s house every 12 h for either 10 days 
(gatiﬂ oxacin group), 14 days (chloramphenicol group), or 
until the patient was cured. The CMA directly observed 
each patient ingesting the single dose of gatiﬂ oxacin and 
two doses of chloramphenicol. The physicians re-
examined the patients on days 8 and 15, and at 1, 3, and 
6 months. All examinations were standardised and 
entered into case record forms.
Complete blood counts were done on days 1, 8, and 15. 
On day 1, serum creatinine, bilirubin, aspartate 
aminotransferase (AST), and alanine aminotransferase 
(ALT) were also checked. Random plasma glucose was 
measured on day 1, day 8, day 15, and 1 month. On 
days 2–7, during the evening visit, the blood glucose was 
measured by ﬁ nger-prick testing (OneTouch SureStep, 
Johnson and Johnson, USA) by the CMAs. Haemoglobin 
A1C was measured at 3 months.
Blood culture was done as described previously16 in all 
patients at admission, in the culture-positive patients on 
day 8, and if symptoms and signs suggested further 
infection.
Stool cultures were done on admission in all patients, 
and in culture-positive patients after completion of 
treatment and at the 1 month, 3 month, and 6 month 
visits in 10 mL of Selenite F broth and incubated at 37°C. 
After the overnight incubation, the broth was subcultured 
onto MacConkey agar and xylose lysine decarboxylase 
agar media.
Isolates were screened using standard biochemical 
tests, and S typhi and S paratyphi A were identiﬁ ed using 
API20E (BioMerieux, Paris, France) and slide agglutination 
with speciﬁ c antisera (MurexBiotech, Dartford, UK).
Minimum inhibitory concentrations (MICs) were 
calculated for amoxicillin, azithromycin, chloramphenicol, 
co-trimoxazole, nalidixic acid, oﬂ oxacin, ciproﬂ oxacin, 
tetracycline, gatiﬂ oxacin, and ceftriaxone by E-test (AB 
Biodisk, Solna, Sweden).
The primary endpoint of this study was the composite 
endpoint of treatment failure, which consisted of any one 
of the following: persistence of fever of more than 37·5°C 
at day 10 of treatment; the need for rescue treatment with 
Chloramphenicol
(n=418)
Gatiﬂ oxacin
(n=426)
Median (IQR) age (years) 15 (8–22) 16 (9–22)
Male sex 261 (62·4%) 279 (65·5%)
Median (IQR) weight (kg) 42 (20–51) 44 (23–53)
Median (IQR) duration of illness before admission (days) 5 (4–7) 5 (4–7)
Median (IQR) temperature at admission (°C) 38·95 (38·2–39·5) 38·90 (38·1–39·4)
Headache 375 (89·7%) 374 (87·8%)
Anorexia 323 (77·3%) 308 (72·5%)
Abdominal pain 181 (43·5%) 157 (37·1%)
Cough 145 (34·8%) 129 (30·4%)
Nausea 120 (28·7%) 136 (32·1%)
Vomiting 86 (20·7%) 81 (19·6%)
Diarrhoea 78 (18·8%) 79 (18·6%)
Constipation 60 (14·4%) 42 (9·9%)
Hepatomegaly 47 (11·2%) 66 (15·5%)
Splenomegaly 64 (15·3%) 55 (12·9%)
Median (IQR) haematocrit (%) 39 (36·0–43·5) 40 (36·0–43·0)
Median (IQR) leucocyte count (×10⁹/L) 6·4 (5·0–8·1) 6·2 (5·1–8·1)
Median (IQR) platelet count (×10⁹/L) 190 (162–219) 193 (165–232)
Median (IQR) AST (U/L) 46 (34–62) 44 (33–60)
Median (IQR) ALT (U/L) 29 (20–43) 30 (20–42)
Salmonella typhi isolated 125 124
Salmonella paratyphi A isolated 50 53
Positive pretreatment faecal cultures 20 (5·3%) 19 (5·1%)
AST=serum aspartate aminotransferase (normal range 12–30 U/L). ALT=serum alanine aminotransferase (normal 
range 13–40 U/L).
Table 1: Baseline characteristics of patients according to treatment group
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ceftriaxone or oﬂ oxacin as judged by the treating 
physician; microbiological failure, deﬁ ned as a positive 
blood culture for S typhi or S paratyphi A on day 8; relapse, 
that is reappearance of culture-conﬁ rmed (including 
mismatch of serotypes [eg, day 1 blood culture positive 
for S typhi and relapse blood culture positive for 
S paratyphi A or vice versa]) or syndromic enteric fever 
on or after day 11 to day 31 in patients who were initially 
categorised as successfully treated; and occurrence of 
enteric-fever-related complications.16 Time to treatment 
failure was deﬁ ned as the time from the ﬁ rst dose of 
treatment until the date of the earliest failure event of 
that patient, and patients without an event were censored 
at the date of their last follow-up visit.
Secondary endpoints were fever clearance time 
(FCT: time from the ﬁ rst dose of treatment given until 
the temperature was ≤37·5°C and the patient remained 
afebrile for at least 48 h); time to relapse until day 31, 
day 62, or month 6 of follow-up; and faecal carriage at 
the follow-up visits at 1, 3, and 6 months. The patients’ 
FCTs were calculated electronically on the basis of 
twice-daily recorded temperatures. Patients without 
recorded fever clearance or relapse were censored at the 
date of their last follow-up visit. To reduce possible bias, 
an investigator not involved in the recruitment of 
patients decided patients’ ﬁ nal outcomes by use of a 
masked database.
Statistical analysis
The trial was designed as a superiority trial with 
the hypothesis that gatiﬂ oxacin was superior to 
chloramphenicol in patients with enteric fever. The 
sample size was calculated to detect a diﬀ erence of 10% 
between the two groups in the proportion of patients 
reaching treatment failure at the two-sided 5% sig niﬁ -
cance level with 80% power. We assumed treatment 
failure rates of 15% in the chloramphenicol and 5% in 
the gatiﬂ oxacin group, leading to a total required sample 
size of 160 patients with culture-conﬁ rmed enteric fever 
per group—320 patients in total. On the basis of results 
from a previous study,10,16 we assumed that about 40% of 
patients who were randomly assigned treatment had 
culture-conﬁ rmed enteric fever. To allow for a loss to 
follow-up rate of about 5%, a total of 853 patients with 
suspected enteric fever were recruited to the trial.
Times to treatment failure, fever clearance, and relapse, 
were analysed by use of survival methods. The cumulative 
incidence of events was calculated with the Kaplan-Meier 
method, and comparisons were based on Cox regression 
models with the treatment group as the only covariate. 
For the primary endpoint (treatment failure), we also 
compared the absolute risk of treatment failure until 
day 31 on the basis of Kaplan-Meier estimates and 
standard errors according to Greenwood’s formula.20 
Additionally, the time to treatment failure was analysed 
in the subgroups deﬁ ned by culture result, pathogen 
(S typhi or S paratyphi A), and age (<16 years or ≥16 years), 
and heterogeneity of the treatment eﬀ ect was tested with 
a Cox regression model that included an interaction 
between treatment and subgroup.
The per-protocol analysis population consisted of all 
patients with blood-culture-conﬁ rmed enteric fever. 
Chloramphenicol (n=175)  Gatiﬂ oxacin (n=177) Comparison
Total number of treatment failures* 14 12 HR 0·86 (95% CI 0·40 to 1·86), p=0·70
Persistent fever at day 10 5 5 ..
Need for rescue treatment 5 3 ..
Microbiological failures 0 2 ..
Relapse until day 31 7 4 ..
Enteric fever related complications 0 0 ..
Probability of treatment failure† 0·08 (95% CI 0·04 to 0·13) 0·07 (95% CI 0·03 to 0·11) RD −0·01 (95% CI −0·07 to 0·04), p=0·64
Median time to fever clearance (days)† 3·95 (95% CI 3·68 to 4·68) 3·9 (95% CI 3·58 to 4·27) HR 1·06 (95% CI 0·86–1·32), p=0·59
Microbiological failures‡ 0/170 (0%) 2/167(1%) §p=0·24
Relapses until day 31 7 4 HR 0·56 (95% CI 0·16–1·91), p=0·35
Number of culture conﬁ rmed relapses 5 3 ..
Number of syndromic relapses 2 1 ..
Probability of relapse until day 31† 0·04 (95% CI 0·01 to 0·07) 0·02 (95% CI 0·00 to 0·05) ..
Relapses until day 62 10 9 HR 0·87 (95% CI 0·35 to 2·15), p=0·77
Number of culture conﬁ rmed relapses 8 5 ..
Number of syndromic relapses 2 4 ..
Probability of relapse until day 62† 0·06 (95% CI 0·02 to 0·10) 0·06 (95% CI 0·02 to 0·09) ..
Relapses after day 62 (all of which were syndromic) 4 10 ..
HR=hazard ratio (based on Cox regression). RD=absolute risk diﬀ erence (based on Kaplan-Meier estimates). *Patients can have more than one type of treatment failure. 
†Kaplan-Meier estimates. ‡Only patients with a blood culture taken on day 8. §Based on Fisher’s exact test.
Table 2: Summary of primary and secondary outcomes for culture-positive patients (per-protocol analysis)
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We also analysed all patients who were assigned 
treatment, with the exception of those patients who 
were mistakenly randomised or withdrew before the 
ﬁ rst dose of study treatment, for treatment failure 
and safety.
All reported tests were done at the two-sided 5% 
signiﬁ cance level, and 95% CIs are reported. All analyses 
were done with the statistical software R version 2.9.1.21
The trial is registered on controlled-trials.com, number 
ISRCTN 53258327.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Of 1151 patients assessed, 853 were assigned treatment; 
844 were analysed, 418 assigned chloramphenicol and 
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Figure 2: Kaplan-Meier estimates for time to treatment failure, fever clearance, and relapse for culture-positive patients
Chloramphenicol (n=418)  Gatiﬂ oxacin (n=426) Comparison
Total number of treatment failures* 26 15 HR 0·57 (95% CI 0·30–1·08), p=0·09
Persistent fever at day 10 7 6 ..
Need for rescue treatment 6 4 ..
Microbiological failures 0 2 ..
Relapse until day 31 16 6 ..
Enteric fever related complications 0 0 ..
Probability of treatment failure† 0·07 (95% CI 0·04 to 0·09) 0·04 (95% CI 0·02 to 0·06) RD −0·03 (95% CI −0·06 to 0·00); p=0·07
Median time to fever clearance (days)† 2·69 (95% CI 2·44 to 2·85) 2·69 (95% CI 2·41 to 2·88) HR 0·99  (95% CI 0·87 to 1·14); p=0·93
Microbiological failures‡ 0/185 (0%) 2/181(1%) p§=0·24
Relapses until day 31 16 6 HR 0·37 (95% CI 0·14 to 0·94); p=0·04
Number of culture conﬁ rmed relapses 8 3 .. 
Number of syndromic relapses 8 3 .. 
Probability of relapse until day 31† 0·04 (95% CI 0·02 to 0·06) 0·02 (95% CI 0·00 to 0·03) ..
Relapses until day 62 23 12 HR 0·50 (95% CI 0·25 to 1·02); p=0·06
Number of culture conﬁ rmed relapses 12 5 .. 
Number of syndromic relapses 11 7 .. 
Probability of relapse until day 62† 0·06 (95% CI 0·04 to 0·08) 0·03 (95% CI 0·01 to 0·05) .. 
HR=hazard ratio (based on Cox regression). RD=absolute risk diﬀ erence (based on Kaplan-Meier estimates). *Patients can have more than one type of treatment failure. 
†Kaplan-Meier estimates. ‡Only patients with a blood culture taken on day 8. §Based on Fisher’s exact test.
Table 3: Summary of primary and secondary outcomes for all patients
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426 gatiﬂ oxacin (ﬁ gure 1). The baseline characteristics of 
the patients were similar in the two treatment groups 
(table 1). The proportion of patients with treatment failure 
was similar in the two treatment groups in patients with 
culture-positive disease (table 2). Of the ﬁ ve patients 
with persistent fever on day 10 in the gatiﬂ oxacin group 
(table 2), two became afebrile on day 11 and did not require 
rescue treatment. The other three patients were eﬀ ectively 
treated with intravenous ceftriaxone 50 mg/kg per day in 
a single dose for 7 days. The ﬁ ve patients in the 
chloramphenicol group who needed rescue treatment 
were successfully treated with oﬂ oxacin 20 mg/kg per day 
in two divided doses per day for 7 days. In all cases, rescue 
treatment was initiated on either day 10 or day 11.
Two patients with microbiological failure in the 
gatiﬂ oxacin group also had persistent fever, and 
responded well to ceftriaxone 50 mg/kg per day in a 
single daily dose for 7 days. All relapse patients, consisting 
of seven (ﬁ ve of whom were culture conﬁ rmed) in the 
chloramphenicol group and four (three of whom were 
culture conﬁ rmed) in the gatiﬂ oxacin group, were also 
treated with oﬂ oxacin 20 mg/kg per day, and recovered.
The secondary outcome measures, which included 
fever clearance time (median 3·95 days in the 
chloramphenicol group and 3·90 in the gatiﬂ oxacin 
group) and time to relapse until day 31 or day 62 also 
showed no signiﬁ cant diﬀ erence between the groups 
(table 2). Only syndromic relapses were documented 
between day 62 and 6 months. Figure 2 shows the 
Kaplan-Meier estimates for the time to treatment 
failure, fever clearance, and relapse.
Stool samples at baseline were positive for S typhi or 
S paratyphi A in 16 (10%) of 157 patients in the 
chloramphenicol group and 14 (9%) of 160 patients in the 
gatiﬂ oxacin group. The proportion of positive stool 
samples at 1–6 months of follow-up was low in both 
groups: at 1 month, only three (2%) of 148 and none of 
154 patients were stool-culture-positive in the chlor-
amphenicol and gatiﬂ oxacin groups (p=0·12), respectively. 
At the end of 3 months, only one patient (in the 
chloramphenicol group) had a positive stool culture, and 
at 6 months no patients had a positive stool culture.
Table 3 shows the primary and secondary endpoints 
in all randomised patients, with the exception of 
patients who were mistakenly randomly allocated 
treatment or withdrew before the ﬁ rst dose of study 
treatment. There was a slightly greater risk of treatment 
failure in patients receiving chloramphenicol (p=0·09). 
Results in selected subgroups (table 4) suggest that this 
is primarily due to a higher failure rate of chlor-
amphenicol in the culture-negative population, 
especially a higher rate  of relapses until day 31 (nine 
[three conﬁ rmed, six syndromic] vs two [both syndromic]; 
HR of time to relapse=0·22, 95% CI 0·05–1·01, p=0·05). 
The median duration of chloram phenicol treatment 
was 9 days (IQR 8–11) in the culture-negative population, 
but there was not a signiﬁ cant association between the 
duration of treatment and the time to relapse (HR=0·93, 
95% CI 0·66–1·30, p=0·66).
Chloramphenicol (n=418) Gatiﬂ oxacin (n=426) p value*
Number of 
patients with 
event (%)
Number of 
events
Number of 
patients with 
event (%)
Number of 
events
Any adverse event 99 (24%) 168 59 (14%) 73 0·0003
Abdominal pain 11 (3%) 12 8 (2%) 8 0·5
Acne 2 (<1%) 2 0 0 0·2
Anorexia 9 (2%) 10 1 (<1%) 1 0·01
Diarrhoea 24 (6%) 26 5 (1%) 5 0·0002
Dizziness 11 (3%) 11 2 (<1%) 2 0·01
Nausea 26 (6%) 29 9 (2%) 9 0·003
Oral candidiasis 4 (1%) 4 0 0 0·06
Vomiting 36 (9%) 39 35 (8%) 35 0·9
Weakness 4 (1%) 4 0 (0%) 0 0·06
All adverse events in this list were non-severe (ie, grade 1 or grade 2) except for one grade 3 dehydration in the 
chloramphenicol group and one grade 3 abdominal pain in the gatiﬂ oxacin group. *Based on Fisher’s exact test.
Table 5: Adverse events: comparison of overall frequency and frequency of selected adverse events 
between the two treatment groups
Chloramphenicol Gatiﬂ oxacin HR (95%CI) p for 
heterogeneity*
Population 
Culture positives 14/175 12/177 0·86 (0·40–1·86, p=0·70) 0·08
Culture negatives 12/243 3/249 0·25 (0·07–0·87, p=0·03) ··
Pathogen 
Salmonella typhi 11/125 8/124 0·73 (0·29–1·82, p=0·50) 0·51
Salmonella paratyphi A 3/50 4/53 1·32 (0·30–5·91, p=0·72) ··
Age 
Less than 16 years 18/222 10/217 0·58 (0·27–1·25, p=0·17) 0·98
16 years or older 8/196 5/209 0·59 (0·19–1·8, p=0·35) ··
*Heterogeneity was tested with a Cox regression model that included an interaction between treatment and 
subgroup.
Table 4: Comparison of treatment failure in the culture-positive and culture-negative population and 
selected subgroups
Chloramphenicol (n=418) Gatiﬂ oxacin* (n=426)
At baseline
Grade 1 2/411 (0·5%) 1/414 (0·2%)
Grade 2 0/411 (0%) 2/414 (0·5%)
On day 8
Grade 1 4/403 (1·0%) 1/188 (0·5%)
Grade 2 3/403 (0·7%) 1/188 (0·5%)
On day 15
Grade 1 1/351 (0·3%) 1/166(0·6%)
Grade 2 0/351 (0%) 0/166 (0%)
Data are n (%) of patients tested. Grade 1 white blood cell (WBC) count 
2000–2500×10⁶/L. Grade 2 WBC count 1500–1999×10⁶/L. No grade 3 or 4 
leucopenia was recorded. *Not all patients who received gatiﬂ oxacin had 
haematological tests on day 8 and day 15.
Table 6: Adverse events: leucopenia
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There was no indication of treatment eﬀ ect hetero-
geneity in the subgroups deﬁ ned by pathogen or age 
(table 4).
Most adverse events were mild (grade 1 and 2; table 5). 
Adverse events were slightly more common in the culture-
positive patients than the culture-negative patients. In the 
chloramphenicol group, 44 (25%) of 175 culture-positive 
patients experienced at least one adverse event (81 events 
in total). In the gatiﬂ oxacin group, 30 (16·9%) of 177 culture-
positive patients experienced at least one adverse event 
(38 events in total). Three patients in the chlorampheni-
col group had a white-blood-cell count between 
1500 and 1999×10⁶ cells per L on day 5–8, and had their 
chloramphenicol stopped. No grade 3 or 4 leucopenia was 
recorded (table 6). No grade 4 hypoglycaemias were 
recorded (table 7), and there were no life-threatening 
complications of enteric fever in this cohort.
Of all the strains of S paratyphi A and S typhi isolated, 
251 (73%) of 345 were nalidixic acid resistant, and two 
(<1%) were multidrug resistant (table 8). Both MDR strains 
were S typhi isolated from patients in the gatiﬂ oxacin 
group. Two S paratyphi A isolates were resistant to 
chloramphenicol, one of which was isolated from a patient 
in the gatiﬂ oxacin group and one of which was isolated 
from a patient in the chlor amphenicol group.
In culture-positive patients, nalidixic acid resistance was 
signiﬁ cantly associated with a slower rate of fever clearance 
(HR 0·57, 95% CI 0·40–0·81, p=0·002) for patients on 
gatiﬂ oxacin, but there was no signiﬁ cant diﬀ erence in 
speed of fever clearance between patients with nalidixic-
acid-resistant strains and those without in the 
chloramphenicol group (0·80, 0·56–1·14, p=0·21).
Discussion
Both chloramphenicol, which is a readily available drug 
in many resource-poor settings, and gatiﬂ oxacin, which is 
a newer generation ﬂ uoroquinolone, had excellent eﬃ  cacy 
Chloramphenicol 
(n=418)
Gatiﬂ oxacin 
(n=426)
p value*
Hyperglycaemia, grade 2†
At baseline 1/414 (0·2%) 2/422 (0·5%) 1·00
On day 2 to day 7‡ 25/407 (6·1%) 42/414 (10·1%) 0·04
On day 8 0/402 (0%) 1/400 (0·3%) 0·50
On day 15 1/366 (0·3%) 0/351 (0·%) 1·00
On month 1 1/375 (0·3%) 0/383 (0·0%) 0·50
Hypoglycaemia, grade 2 or worse§
At baseline 4/414 (1.0%) 4/422 (1·0%) 1·00
On day 2 to day 7‡ 1/407 (0·3%) 1/414 (0·2%) 1·00
On day 8 2/402 (0·5%) 2/400 (0·5%) 1·00
On day 15 4/366 (1·1%) 3/351 (0·9%) 1·00
On month 1 3/375 (0·8%) 4/383 (1·0%) 1·00
HbA1c>6%
On month 3 22/351 (6·3%) 20/359 (5·6%) 0·8
Data are n (%) of patients tested for abnormal blood glucose. *Based on Fisher’s 
exact test. †Grade 2 non-fasting plasma glucose 161–250 mg/dL. No grade 3 or 4 
hyperglycaemias were recorded. ‡On days 2 to 7, all patients were monitored with 
ﬁ ngerstick glucose testing. §Grade 2 non-fasting plasma glucose 40–54 mg/dL. 
One grade 3 hypoglycaemia (30–39 mg/dL) was recorded at baseline, and two on 
day 15 (one in each group). No grade 4 hypoglycaemias were recorded.
Table 7: Adverse events: dysglycaemia
Salmonella paratyphi A 
(n=103)
Salmonella typhi 
(n=249)
p value
Chloramphenicol
MIC 50 (μg/mL) 8·00 4·00 ·· 
MIC 90 (μg/mL) 12·00 8·00 <0·0001
Range 2·00–64·00 1·50 to >256·00 ··
Amoxicillin
MIC 50 (μg/mL) 1·00 0·50 ··
MIC 90 (μg/mL) 2·00 1·00 <0·0001
Range 0·50–3·00 0·04 to >256·00 ··
Cotrimoxazole
MIC 50 (μg/mL) 0·12 0·03 ··
MIC 90 (μg/mL) 0·19 0·06 <0·0001
Range 0·02–0·38 0·01 to >32·00 ··
Tetracycline
MIC 50 (μg/mL) 1·50 1·00 ··
MIC 90 (μg/mL) 2·90 2·00 <0·0001
Range 0·50–8·00 0·38 to >256·00 ··
Ceftriaxone
MIC 50 (μg/mL) 0·19 0·12 ·· 
MIC 90 (μg/mL) 0·25 0·19 <0·0001
Range 0·12–0·38 0·05–0·25 ··
Azithromycin
MIC 50 (μg/mL) 12·00 6·00 ··
MIC 90 (μg/mL) 16·00 12·00 <0·0001
Range 1·00–48·00 0·38–24·00 ··
Nalidixic acid
MIC 50 (μg/mL) >256·00 >256·00 ··
MIC 90 (μg/mL) >256·00 >256·00 <0·0001
Range 1·50 to >256·00 0·38 to >256·00 ··
Ciproﬂ oxacin
MIC 50 (μg/mL) 0·50 0·25 ··
MIC 90 (μg/mL) 0·75 0·38 <0·0001
Range 0·02–1·50 0·00–1·00 ·· 
Oﬂ oxacin
MIC 50 (μg/mL) 1·50 0·38  ··
MIC 90 (μg/mL) 2·00 0·50 <0·0001
Range 0·06–6·00 0·02–4·00 ··
Gatiﬂ oxacin
MIC 50 (μg/mL) 0·50 0·12  ··
MIC 90 (μg/mL) 0·50 0·19 <0·0001
Range 0·02–1·50 0·00–1·00 ·· 
Multidrug-resistant isolates 0 (0%) 2 (0·82%) 1·00
Nalidixic-acid-resistant isolates 92 (90·2%) 159 (65·43%) <0·0001
*102 S typhi and 243 S paratyphi A were available for MIC testing. MIC50/90=concentration at which 50% and 90% 
of the organisms, respectively, are inhibited. Multidrug resistance is deﬁ ned as resistance to chloramphenicol, 
ampicillin, and co-trimoxazole. Comparisons are based on Wilcoxon test for continuous data and Fisher’s exact test 
for categorical data.
Table 8: Antimicrobial susceptibility results: minimum inhibitory concentrations (MICs)* and resistance 
proﬁ le of Salmonella paratyphi A and S typhi isolates
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in the treatment of culture-positive enteric fever, and both 
drugs had a favourable side-eﬀ ect proﬁ le. Gatiﬂ oxacin did 
as well as, but was not superior to, chloramphenicol in an 
area with a high proportion (73%) of nalidixic-acid-
resistant S typhi and S paratyphi A strains, but almost no 
chloramphenicol resistance.
With 844 patients analysed (ﬁ gure 1), this is to our 
knowledge the largest randomised controlled trial in 
enteric fever, and the biggest trial comparing 
chloramphenicol with a ﬂ uoroquinolone. This is also the 
ﬁ rst trial to compare chloramphenicol to a ﬂ uoroquin-
olone in a predominantly paediatric population (table 1). 
We also assessed the—to our knowledge—largest 
population of blood-culture-negative patients with 
enteric fever. In patients who had blood-culture-negative 
syndromic enteric fever, both drugs were eﬀ ective, but 
gatiﬂ oxacin was more eﬀ ective in reducing syndromic 
clinical relapse.
There are underlying technical issues for typhoid and 
enteric fever treatment trials. One of the central 
limitations is the low sensitivity of the blood culture 
technique, which is estimated to be between 40% and 
50%.22 That most patients with enteric fever are 
categorised as syndromic, and treated empirically 
without a deﬁ nitive diagnosis for enteric fever, is 
therefore not surprising. For the same reason, 
syndromic relapse was included as an outcome event in 
the a-priori deﬁ ned analysis plan in this study.
The antibiotics used in this trial show diﬀ erent 
pharmacological properties. Gatiﬂ oxacin has important 
features likely to help with treatment adherence 
compared with chloramphenicol: gatiﬂ oxacin only 
needs to be taken once a day for 7 days, whereas 
chloramphenicol requires four doses per day for 14 days. 
There was no diﬀ erence between the two drugs in terms 
of treatment failure and fever clearance time in the 
culture-positive group; however, the adverse eﬀ ects 
proﬁ le showed that anorexia, nausea, diarrhoea, and 
dizziness, were signiﬁ cantly worse in the chlor-
amphenicol group (table 5).
We monitored blood glucose levels closely in both 
treatment groups chieﬂ y because of a recent Canadian, 
retrospective case-control study of 1·4 million elderly 
individuals (mean age 77) that showed that gatiﬂ oxacin 
was associated with dysglycaemia.23 After this report, 
gatiﬂ oxacin was withdrawn from the US and Canadian 
markets. In our trial, between day 2 and day 7, the pro-
portion of patients with a high (grade 2; 161–250 mg/dL) 
non-fasting blood glucose on ﬁ nger-stick testing was 
higher in the gatiﬂ oxacin group versus the chloram-
phenicol group. However, there was no diﬀ erence on 
days 15 and days 30. Similarly, at the end of 3 months, 
HbA1c concentrations were not diﬀ erent in the two 
groups (table 7). Additionally, previous studies using 
gatiﬂ oxacin in a younger population have not reported 
clinically relevant dysglycaemia.24 Finally, in another 
study comparing gatiﬂ oxacin with oﬂ oxacin for the 
treatment of enteric fever that we are doing 
(ISRCTN63006567), we have not recorded any dys-
glycaemia. The gatiﬂ oxacin-associated dysglycaemia in 
the Canadian study might be attributed to an age-related 
decrease in renal function in elderly patients receiving 
gatiﬂ oxacin, and there might well be a pharmacokinetic 
or pharmacodynamic rationale for a potential age-
related dose reduction.25 Treatment options for enteric 
fever are clearly limited. Gatiﬂ oxacin is an eﬃ  cacious 
drug for the treatment of enteric fever in young and 
otherwise healthy patients, and should be available for 
indication in this neglected disease. It would be prudent 
not to use gatiﬂ oxacin in patients over 50 years of age, 
or in patients with comorbidities such as diabetes or 
renal failure.
Most enteric fever trials are done in an inpatient setting, 
which does not reﬂ ect reality in developing countries, 
where most uncomplicated enteric fever treatment is 
done in an outpatient setting.1,8 Our trial was completed 
Panel: Research in context
Systematic review
We searched Medline for the terms “gatiﬂ oxacin”, 
“chloramphenicol”, “clinical trial”, and “typhoid/enteric fever”. 
We also identiﬁ ed relevant articles from a recent Cochrane 
review,7 WHO typhoid guidelines,22 and a recent meta-analysis 
of ﬂ uoroquinolones versus other antibiotics in the treatment 
of typhoid fever.26 There were ten trials27–36 in the 
meta-analysis that compared ﬂ uoroquinolones with 
chloramphenicol. Multidrug-resistant strains were 
absent in all but one trial,27 and nalidixic acid resistance was 
only reported in one trial27 in which there were no nalidixic-
acid-resistant strains. The meta-analysis concluded that 
ﬂ uoroquinolones were not signiﬁ cantly diﬀ erent from 
chloramphenicol for clinical failure or microbiological failure 
in an adult population. However, the sample sizes of the trials 
included in the analysis were small, and there was a paucity 
of paediatric data. There were only two previous trials 
of gatiﬂ oxacin for the treatment of uncomplicated enteric 
fever: one from Nepal and one from Vietnam.16,17
Interpretation
Gatiﬂ oxacin was not better than chloramphenicol in children 
and adults in Nepal with enteric fever. Both gatiﬂ oxacin 
and chloramphenicol showed similar eﬃ  cacy in the 
treatment of blood-culture-positive enteric fever in a setting 
with strains of S typhi and S paratyphi A fully sensitive 
to chloramphenicol and resistant to nalidixic acid. Our trial 
showed that both in the adult and paediatric population 
gatiﬂ oxacin was not better than chloramphenicol. However, 
in a developing-country setting like Nepal in a young 
population where this disease predominates, gatiﬂ oxacin 
should be the preferred choice because of its shorter 
treatment duration, fewer adverse events, and lower cost 
in the treatment of enteric fever.
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in an outpatient setting with the help of CMAs, as 
described in our earlier trial.16 This model is more 
applicable to developing countries.
A very attractive feature, especially for resource-poor 
settings, is the inexpensiveness of the antibiotics 
studied here. The average price for a 14-day treat-
ment course with chloramphenicol was US$7. The 
average price for a 7-day treatment with gatiﬂ oxacin 
was US$1·5.
A recent Cochrane review (panel) of ﬂ uoroquinolones 
for the treatment of enteric fever pointed out the 
weaknesses of typhoid fever treatment trials that have 
small sample sizes, inadequate randomisation and 
concealment, incomplete follow-up, and a lack of 
paediatric patients and standardised endpoints.7 We 
tried to address these criticisms by recruiting a large 
sample of patients, by percisely deﬁ ning our endpoints, 
and by attempting to reduce bias within the limits of an 
open trial.
Two other trials used gatiﬂ oxacin for the treatment of 
enteric fever (panel). 16,17 The ﬁ rst trial compared 
gatiﬂ oxacin to ceﬁ xime, and enrolled children and adult 
outpatients in Nepal.16 This trial had to be prematurely 
stopped on the advice of the independent data safety 
monitoring committee because of the poor performance 
of ceﬁ xime. There was a high rate of overall treatment 
failure (persistent fever at day 7, relapse and death) with 
29 (38%) of 70 patients failing in the ceﬁ xime group 
compared with three (3%) of 88 patients in the 
gatiﬂ oxacin group (HR 0·08, 0·03–0·28, p<0·001). 
There was one death in the ceﬁ xime group.
The second trial compared gatiﬂ oxacin with 
azithromycin, and was done in paediatric and adult in-
patients in Vietnam.17 There was no statistical diﬀ erence 
between the two antibiotics, and both showed excellent 
eﬃ  cacy. The median fever clearance times were 106 h 
in both groups. 13 (9%) of 145 patients in the gatiﬂ oxacin 
group had overall treatment failure as did 13 (9%) 
of 140 in the azithromycin group (HR 0·93, 0·43–2·0, 
p=0·85). Both trials were done in regions with high 
rates of nalidixic-acid-resistant strains: 83% in Nepal 
and 96% in Vietnam. In previous trials in Vietnam, 
patients treated with the older generation ﬂ uoro-
quinolone oﬂ oxacin given at 20 mg/kg per day showed 
high clinical failure rates of 36% (23 of 63 patients) and 
prolonged mean fever clearance times of 8·2 days 
(95% CI 7·2–9·2 days).37
Gatiﬂ oxacin is not superior to chloramphenicol in 
terms of eﬃ  cacy. However, on the basis of its shorter 
treatment duration, fewer adverse events, and lower 
cost, gatiﬂ oxacin should be the preferred treatment of 
enteric fever in developing countries.
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